The TGF- ligand traps Bintrafusp alfa (a bifunctional conjugate that binds TGF- and PD-L1), AVID200 (a computationally designed trap of TGF- receptor ectodomains fused to an Fc website) and Luspatercept (a recombinant fusion that links the?activin receptor IIb to IgG) present new ways to battle difficult-to-treat cancers. drug classes that have been evaluated in completed … Continue reading The TGF- ligand traps Bintrafusp alfa (a bifunctional conjugate that binds TGF- and PD-L1), AVID200 (a computationally designed trap of TGF- receptor ectodomains fused to an Fc website) and Luspatercept (a recombinant fusion that links the?activin receptor IIb to IgG) present new ways to battle difficult-to-treat cancers